Although several HDAC inhibitors are under investigation for the treatment of DLBCL, these compounds, including vorinostat, belinostat, and panobinostat, showed limited activities or unexpected toxicities in clinical trials [14]. Here, HDAC9 is linked to diffuse large B-cell lymphoma.